| Endometriosis
Lupron Depot vs Zoladex
Side-by-side clinical, coverage, and cost comparison for endometriosis.Deep comparison between: Lupron Depot vs Zoladex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoladex has a higher rate of injection site reactions vs Lupron Depot based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoladex but not Lupron Depot, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lupron Depot
Zoladex
At A Glance
IM injection
Every 3 months
GnRH agonist
SC injection
Every 28 days
GnRH agonist
Indications
- Endometriosis
- Uterine Fibroids
- Prostate carcinoma
- Endometriosis
- Abnormal uterine bleeding
- Breast Carcinoma
Dosing
Endometriosis 11.25 mg IM every 3 months for 1 to 2 doses (up to 6 months); may be administered alone or with norethindrone acetate 5 mg daily add-back. Retreatment for up to 6 additional months requires norethindrone acetate add-back; total treatment duration must not exceed 12 months.
Uterine Fibroids One IM injection of 11.25 mg providing a single 3-month treatment course.
Prostate carcinoma (Stage B2-C) 3.6 mg SC every 28 days starting 8 weeks before radiotherapy, in combination with flutamide, continued during radiation therapy; alternatively, a 10.8 mg depot may follow the initial 3.6 mg depot.
Prostate carcinoma (advanced) 3.6 mg SC every 28 days; intended for long-term administration.
Endometriosis 3.6 mg SC every 28 days for 6 months.
Abnormal uterine bleeding One or two 3.6 mg SC depots given 4 weeks apart; surgery performed at 4 weeks after one depot, or within 2-4 weeks after the second depot.
Breast Carcinoma 3.6 mg SC every 28 days; intended for long-term administration.
Contraindications
- Hypersensitivity to GnRH, GnRH agonist analogs including leuprolide acetate, or any excipient in LUPRON DEPOT 11.25 mg
- Undiagnosed abnormal uterine bleeding
- Pregnancy
- When norethindrone acetate is co-administered, contraindications to norethindrone acetate also apply
- Known hypersensitivity to GnRH, GnRH agonist analogues, or any component of ZOLADEX
- Pregnancy (except when used for palliative treatment of advanced breast cancer)
Adverse Reactions
Most common (>=5%) Hot flashes/sweats, headache, vaginitis, depression/emotional lability, general pain, weight gain/loss, nausea/vomiting, decreased libido, dizziness, acne, skin reactions
Serious Urinary tract infection, renal calculus, depression
Postmarketing Rash, urticaria, anaphylaxis, mood swings, depression, suicidal ideation, convulsion, peripheral neuropathy, serious liver injury, injection site reactions including induration/abscess/necrosis, spinal fracture, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, pituitary apoplexy
Most common (>10%) in men Hot flashes, sexual dysfunction, decreased erections, lower urinary tract symptoms
Most common (>20%) in women Hot flushes, headache, sweating, acne, emotional lability, depression, decreased libido, vaginitis, breast atrophy, seborrhea, peripheral edema
Serious Tumor flare, ureteral obstruction, spinal cord compression, pituitary apoplexy
Postmarketing Osteoporosis, bone fracture, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack, ovarian cyst, pituitary adenoma, SJS/TEN, DRESS, AGEP, erythema multiforme, psychotic disorders, suicidal ideation, convulsions
Pharmacology
Long-acting GnRH agonist that causes initial stimulation followed by prolonged suppression of pituitary gonadotropins, resulting in decreased gonadal steroid secretion and quiescence of estrogen-dependent tissues; effect is reversible upon discontinuation.
ZOLADEX is a synthetic decapeptide analogue of GnRH that inhibits pituitary gonadotropin secretion; chronic administration suppresses serum testosterone in males to castrate levels and reduces serum estradiol in females to postmenopausal levels, leading to regression of hormone-sensitive tumors and accessory sex organ regression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lupron Depot
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Zoladex
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Lupron Depot
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (2/8) · Qty limit (2/8)
Zoladex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lupron Depot
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Zoladex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lupron Depot.
No savings programs available for Zoladex.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Lupron DepotView full Lupron Depot profile
ZoladexView full Zoladex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.